HUP0204333A3 - Use of csaids in rhinovirus infection - Google Patents

Use of csaids in rhinovirus infection

Info

Publication number
HUP0204333A3
HUP0204333A3 HU0204333A HUP0204333A HUP0204333A3 HU P0204333 A3 HUP0204333 A3 HU P0204333A3 HU 0204333 A HU0204333 A HU 0204333A HU P0204333 A HUP0204333 A HU P0204333A HU P0204333 A3 HUP0204333 A3 HU P0204333A3
Authority
HU
Hungary
Prior art keywords
csaids
rhinovirus infection
rhinovirus
infection
Prior art date
Application number
HU0204333A
Other languages
Hungarian (hu)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of HUP0204333A2 publication Critical patent/HUP0204333A2/en
Publication of HUP0204333A3 publication Critical patent/HUP0204333A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
HU0204333A 1999-09-17 2000-09-15 Use of csaids in rhinovirus infection HUP0204333A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15449499P 1999-09-17 1999-09-17
PCT/US2000/025386 WO2001019322A2 (en) 1999-09-17 2000-09-15 Use of csaids in rhinovirus infection

Publications (2)

Publication Number Publication Date
HUP0204333A2 HUP0204333A2 (en) 2003-05-28
HUP0204333A3 true HUP0204333A3 (en) 2004-07-28

Family

ID=22551566

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0204333A HUP0204333A3 (en) 1999-09-17 2000-09-15 Use of csaids in rhinovirus infection

Country Status (17)

Country Link
EP (1) EP1223924A4 (en)
JP (1) JP2003516314A (en)
KR (1) KR20020032591A (en)
CN (1) CN1382044A (en)
AR (1) AR025691A1 (en)
AU (1) AU7584500A (en)
BR (1) BR0014041A (en)
CA (1) CA2385722A1 (en)
CO (1) CO5200855A1 (en)
CZ (1) CZ2002939A3 (en)
HU (1) HUP0204333A3 (en)
IL (1) IL148329A0 (en)
NO (1) NO20021301L (en)
PL (1) PL363116A1 (en)
TR (1) TR200200673T2 (en)
WO (1) WO2001019322A2 (en)
ZA (1) ZA200202060B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
EP1337255A4 (en) * 2000-10-19 2006-01-25 Smithkline Beecham Corp Use of p38 inhibitors for the treatment of inflammation-enhanced cough
JP4524072B2 (en) 2000-10-23 2010-08-11 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー New compounds
AU2003230692A1 (en) * 2002-03-20 2003-10-08 Elan Pharma International Ltd. Nanoparticulate compositions of map kinase inhibitors
RU2004132847A (en) * 2002-04-05 2006-08-20 Берингер Ингельхайм Фарма Гмбх Унд Ко.Кг (De) METHOD FOR TREATING HYPERSECRATION OF SLIMAS
JP2005538066A (en) * 2002-07-09 2005-12-15 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト Novel pharmaceutical composition using novel anticholinergic agent and p38 kinase inhibitor
JP4593953B2 (en) * 2004-03-30 2010-12-08 杏林製薬株式会社 Rhinovirus infection prophylaxis
US20060030550A1 (en) * 2004-08-04 2006-02-09 Lithgow Theodore L Pharmaceutical formulations
AR053346A1 (en) 2005-03-25 2007-05-02 Glaxo Group Ltd COMPOSITE DERIVED FROM 8H -PIRIDO (2,3-D) PIRIMIDIN -7 ONA 2,4,8- TRISUSTITUTED PHARMACEUTICAL COMPOSITION AND USE TO PREPARE A COMPOSITION FOR TREATMENT AND PROFILXIS OF A DISEASE MEDIATED BY KINASE CSBP / RK / P38
WO2009116944A1 (en) 2008-03-20 2009-09-24 Krister Tano Use of a substance for manufacturing of a medicament for treatment of common cold
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
WO2011035128A1 (en) * 2009-09-17 2011-03-24 Mutual Pharmaceutical Company, Inc. Method of treating asthma with antiviral agents
GB201010193D0 (en) * 2010-06-17 2010-07-21 Respivert Ltd Medicinal use
GB201010196D0 (en) * 2010-06-17 2010-07-21 Respivert Ltd Methods
US11389663B2 (en) 2011-04-01 2022-07-19 Bioregentech, Inc. Laser assisted wound healing protocol and system
US11730760B2 (en) 2011-04-01 2023-08-22 The Bioregentech Institute, Inc. Laser assisted wound healing protocol and system
GB201611712D0 (en) 2016-07-02 2016-08-17 Hvivo Services Ltd Methods and compounds for the treatment or prevention of severe or persistent influenza
PL3691620T3 (en) 2017-10-05 2022-11-21 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
GB201721793D0 (en) * 2017-12-22 2018-02-07 Hvivo Services Ltd Methods and compunds for the treatment or prevention of hypercytokinemia and severe influenza
WO2021216754A1 (en) * 2020-04-21 2021-10-28 Spring Discovery, Inc. Use of p38 mapk inhibitors for prevention and treatment of aging and aging-related disorders and for boosting an immune system

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3927216A (en) * 1971-06-01 1975-12-16 Icn Pharmaceuticals 1,2,4-Triazol E-3-carboxamides for inhibiting virus infections
US3984396A (en) * 1971-06-01 1976-10-05 Icn Pharmaceuticals, Inc. 1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters
US5656644A (en) * 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
IL118544A (en) * 1995-06-07 2001-08-08 Smithkline Beecham Corp Imidazole derivatives, process for their preparation and pharmaceutical compositions comprising them
AP9700912A0 (en) * 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles
WO2000040243A1 (en) * 1999-01-08 2000-07-13 Smithkline Beecham Corporation Novel compounds

Also Published As

Publication number Publication date
CN1382044A (en) 2002-11-27
HUP0204333A2 (en) 2003-05-28
ZA200202060B (en) 2003-05-28
PL363116A1 (en) 2004-11-15
JP2003516314A (en) 2003-05-13
AR025691A1 (en) 2002-12-11
AU7584500A (en) 2001-04-17
CZ2002939A3 (en) 2002-11-13
TR200200673T2 (en) 2002-12-23
CA2385722A1 (en) 2001-03-22
EP1223924A4 (en) 2004-07-14
WO2001019322A2 (en) 2001-03-22
WO2001019322A3 (en) 2001-10-04
BR0014041A (en) 2003-07-15
EP1223924A2 (en) 2002-07-24
CO5200855A1 (en) 2002-09-27
KR20020032591A (en) 2002-05-03
IL148329A0 (en) 2002-09-12
NO20021301D0 (en) 2002-03-15
NO20021301L (en) 2002-05-16

Similar Documents

Publication Publication Date Title
HUP0204333A3 (en) Use of csaids in rhinovirus infection
GB9915414D0 (en) Medical use
GB0004167D0 (en) 1-piperidinyl-propan-2-ol derivatives and their use as therapeutic agents
PL352330A1 (en) Derivatives of pyridopyranoazepine, making of same and use of same in therapy
IL147503A0 (en) Oxazolidinone compounds and methods of preparation and use thereof
AU4289100A (en) Dihydropyrimidines and their use in the treatment of hepatitis
HU0001396D0 (en) 3-amino-3-arylpropan-1-al derivatives and their use
PL352333A1 (en) Dihydrobenzodiazepines and use of same in treatment of dislipidemia
GB9907965D0 (en) Medical use
EP1161451A4 (en) Human endokine alpha and methods of use
GB9929318D0 (en) Macrocyclic compounds and their use
PL350963A1 (en) Use of arylalkanoylpyridazines
GB9925379D0 (en) Medical use
GB0018887D0 (en) Compound and their therapeutic use
AU4116500A (en) The use of alpha lipoic acid in the antimetastatic treatment
AU3554800A (en) Use of porphyrin derivatives in aquariums
GB9929581D0 (en) Comjpositions and their use
GB9905315D0 (en) Therapy and use of compounds in therapy
GB9905307D0 (en) Therapy and use of compounds in therapy
GB0022210D0 (en) Treatment of infection in animals
GB0012401D0 (en) Treatment of infection in animals
GB9901904D0 (en) RTherapeutic use of human pheramones
IL145242A0 (en) Treatment of hiatial hernia
GB9920996D0 (en) Improvements in the human support of catheter leg-bags
GB9921562D0 (en) Preparation and use of potential - controlled membranes

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees